Fabre-Kramer Receives Decision From FDA on Gepirone ER for Major Depressive Disorder

Fabre-Kramer Pharmaceuticals Inc. (FKP) and GlaxoSmithKline announced that the U.S. Food and Drug Administration (FDA) has issued a not approvable letter for the new drug application for gepirone extended- release (ER) tablets, submitted for the treatment of adults with major depressive disorder.
CNN Money